 Christene Huang
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Swine | 40 | 2022 | 687 | 2.270 |
Why?
| | Diphtheria Toxin | 13 | 2020 | 51 | 2.090 |
Why?
| | Immunotoxins | 12 | 2022 | 33 | 1.960 |
Why?
| | Swine, Miniature | 24 | 2016 | 70 | 1.790 |
Why?
| | Transplantation Conditioning | 9 | 2016 | 149 | 1.270 |
Why?
| | Transplantation Chimera | 11 | 2016 | 51 | 1.200 |
Why?
| | Galectin 3 | 3 | 2022 | 18 | 1.190 |
Why?
| | Lymphocyte Depletion | 9 | 2016 | 115 | 1.190 |
Why?
| | Blood Component Removal | 2 | 2018 | 26 | 1.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 11 | 2016 | 519 | 1.090 |
Why?
| | CD3 Complex | 5 | 2013 | 92 | 1.030 |
Why?
| | Graft vs Host Disease | 6 | 2016 | 212 | 0.870 |
Why?
| | Swine Diseases | 5 | 2015 | 8 | 0.820 |
Why?
| | Recombinant Fusion Proteins | 10 | 2020 | 613 | 0.790 |
Why?
| | Skin Transplantation | 5 | 2016 | 57 | 0.710 |
Why?
| | Graft Rejection | 9 | 2016 | 511 | 0.690 |
Why?
| | Lymphoproliferative Disorders | 5 | 2015 | 46 | 0.690 |
Why?
| | Bone Marrow Transplantation | 7 | 2015 | 237 | 0.660 |
Why?
| | Isoantibodies | 5 | 2016 | 52 | 0.650 |
Why?
| | Histocompatibility Antigens | 3 | 2015 | 98 | 0.620 |
Why?
| | Animals | 58 | 2023 | 31565 | 0.620 |
Why?
| | Interleukin-2 | 5 | 2020 | 413 | 0.590 |
Why?
| | Cell Transplantation | 2 | 2010 | 35 | 0.590 |
Why?
| | Transplantation, Homologous | 8 | 2016 | 377 | 0.580 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 337 | 0.570 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 193 | 0.560 |
Why?
| | Immunity, Humoral | 3 | 2015 | 112 | 0.540 |
Why?
| | Transplantation, Haploidentical | 1 | 2016 | 7 | 0.540 |
Why?
| | Lymphocyte Transfusion | 1 | 2016 | 19 | 0.540 |
Why?
| | Blood Donors | 1 | 2016 | 84 | 0.500 |
Why?
| | Receptors, CCR4 | 5 | 2020 | 15 | 0.480 |
Why?
| | Graft Survival | 8 | 2015 | 443 | 0.480 |
Why?
| | T-Lymphocytes | 7 | 2015 | 1735 | 0.470 |
Why?
| | Transplantation Immunology | 4 | 2012 | 30 | 0.470 |
Why?
| | Transplantation Tolerance | 5 | 2014 | 30 | 0.470 |
Why?
| | Autoimmunity | 2 | 2022 | 812 | 0.460 |
Why?
| | Cell Lineage | 2 | 2006 | 308 | 0.440 |
Why?
| | Pichia | 8 | 2017 | 19 | 0.440 |
Why?
| | Immunity, Cellular | 3 | 2013 | 247 | 0.430 |
Why?
| | Cyclosporine | 7 | 2016 | 161 | 0.410 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 5 | 2020 | 66 | 0.410 |
Why?
| | Tissue Engineering | 1 | 2016 | 364 | 0.410 |
Why?
| | Inbreeding | 2 | 2009 | 16 | 0.370 |
Why?
| | Antibodies | 2 | 2012 | 365 | 0.360 |
Why?
| | Inflammation | 4 | 2022 | 2464 | 0.360 |
Why?
| | Transplantation, Heterologous | 4 | 2021 | 180 | 0.350 |
Why?
| | Hematopoietic Stem Cells | 4 | 2013 | 338 | 0.350 |
Why?
| | Whole-Body Irradiation | 4 | 2016 | 72 | 0.350 |
Why?
| | Immune Tolerance | 5 | 2015 | 321 | 0.350 |
Why?
| | Umbilical Cord | 1 | 2010 | 80 | 0.340 |
Why?
| | Transplantation | 2 | 2012 | 23 | 0.330 |
Why?
| | Flow Cytometry | 11 | 2020 | 1075 | 0.330 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 94 | 0.320 |
Why?
| | Liver Diseases | 2 | 2022 | 254 | 0.310 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2020 | 40 | 0.310 |
Why?
| | CTLA-4 Antigen | 3 | 2013 | 76 | 0.300 |
Why?
| | Thymus Gland | 4 | 2015 | 296 | 0.280 |
Why?
| | Immunosuppressive Agents | 5 | 2015 | 641 | 0.270 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2007 | 91 | 0.270 |
Why?
| | Bone Marrow | 2 | 2010 | 243 | 0.270 |
Why?
| | Chimerism | 1 | 2006 | 28 | 0.270 |
Why?
| | Fetal Blood | 1 | 2007 | 268 | 0.250 |
Why?
| | Hematologic Neoplasms | 1 | 2007 | 136 | 0.250 |
Why?
| | Recombinant Proteins | 7 | 2020 | 1228 | 0.250 |
Why?
| | Galectins | 2 | 2022 | 22 | 0.240 |
Why?
| | Cell Line, Tumor | 4 | 2017 | 2700 | 0.240 |
Why?
| | Papio | 3 | 2015 | 96 | 0.230 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1257 | 0.220 |
Why?
| | Fiber Optic Technology | 1 | 2023 | 18 | 0.220 |
Why?
| | Porphyrins | 1 | 2023 | 16 | 0.220 |
Why?
| | Skin | 3 | 2018 | 653 | 0.220 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2012 | 170 | 0.220 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 19 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2012 | 350 | 0.210 |
Why?
| | Antibody Specificity | 2 | 2017 | 175 | 0.210 |
Why?
| | Histocompatibility Testing | 4 | 2015 | 115 | 0.200 |
Why?
| | Herpesviridae | 1 | 2022 | 21 | 0.200 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 13 | 0.200 |
Why?
| | Muscle Stretching Exercises | 1 | 2022 | 17 | 0.200 |
Why?
| | Yoga | 1 | 2022 | 28 | 0.200 |
Why?
| | Meditation | 1 | 2022 | 34 | 0.190 |
Why?
| | Skin Neoplasms | 2 | 2020 | 754 | 0.190 |
Why?
| | Major Histocompatibility Complex | 4 | 2005 | 217 | 0.190 |
Why?
| | Immunoglobulin G | 2 | 2017 | 766 | 0.190 |
Why?
| | Leukapheresis | 3 | 2013 | 21 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 72 | 0.190 |
Why?
| | Mice, SCID | 5 | 2017 | 312 | 0.180 |
Why?
| | Histocompatibility | 3 | 2015 | 26 | 0.180 |
Why?
| | Endogenous Retroviruses | 1 | 2021 | 19 | 0.180 |
Why?
| | Spleen | 3 | 2007 | 485 | 0.180 |
Why?
| | Mice, Inbred NOD | 5 | 2017 | 552 | 0.170 |
Why?
| | Postoperative Complications | 3 | 2022 | 2122 | 0.170 |
Why?
| | Lymphoma | 1 | 2021 | 176 | 0.170 |
Why?
| | Disease Models, Animal | 7 | 2015 | 3498 | 0.170 |
Why?
| | Colony-Forming Units Assay | 5 | 2006 | 88 | 0.170 |
Why?
| | Amino Acid Sequence | 6 | 2015 | 1981 | 0.170 |
Why?
| | Time Factors | 7 | 2017 | 6077 | 0.160 |
Why?
| | Hematologic Diseases | 2 | 2012 | 55 | 0.160 |
Why?
| | Base Sequence | 6 | 2015 | 2114 | 0.160 |
Why?
| | Kidney Transplantation | 4 | 2005 | 538 | 0.160 |
Why?
| | B7-1 Antigen | 3 | 2013 | 53 | 0.160 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2783 | 0.160 |
Why?
| | Interleukin-3 | 2 | 2011 | 23 | 0.150 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 17 | 0.150 |
Why?
| | Lymphocyte Culture Test, Mixed | 4 | 2014 | 41 | 0.150 |
Why?
| | Antibodies, Heterophile | 2 | 2015 | 13 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 247 | 0.140 |
Why?
| | Haplotypes | 2 | 2012 | 448 | 0.140 |
Why?
| | Papio hamadryas | 2 | 2013 | 5 | 0.140 |
Why?
| | Antibody Affinity | 1 | 2017 | 51 | 0.140 |
Why?
| | Antigens, CD19 | 1 | 2017 | 91 | 0.130 |
Why?
| | Humans | 26 | 2022 | 114045 | 0.130 |
Why?
| | Heterografts | 2 | 2013 | 117 | 0.130 |
Why?
| | Antigen-Presenting Cells | 1 | 2016 | 150 | 0.130 |
Why?
| | Immunoconjugates | 1 | 2017 | 87 | 0.130 |
Why?
| | B-Lymphocytes | 2 | 2015 | 762 | 0.130 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 4 | 0.130 |
Why?
| | Gene Expression | 5 | 2012 | 1417 | 0.130 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 990 | 0.130 |
Why?
| | Lymphatic Irradiation | 1 | 2015 | 9 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2022 | 695 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 334 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 326 | 0.120 |
Why?
| | Lymphoma, B-Cell | 2 | 2013 | 87 | 0.120 |
Why?
| | Composite Tissue Allografts | 1 | 2014 | 8 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 787 | 0.120 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 386 | 0.120 |
Why?
| | Galactosyltransferases | 2 | 2013 | 11 | 0.120 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2012 | 20 | 0.120 |
Why?
| | Lymphocyte Count | 2 | 2022 | 132 | 0.120 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2015 | 107 | 0.110 |
Why?
| | Mice | 10 | 2022 | 14843 | 0.110 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 52 | 0.110 |
Why?
| | Leukocytes | 1 | 2015 | 272 | 0.110 |
Why?
| | Retinal Degeneration | 1 | 2014 | 30 | 0.110 |
Why?
| | Plasmids | 2 | 2011 | 343 | 0.110 |
Why?
| | Antilymphocyte Serum | 1 | 2013 | 60 | 0.110 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2014 | 56 | 0.110 |
Why?
| | Lung Transplantation | 1 | 2015 | 244 | 0.110 |
Why?
| | Stem Cell Transplantation | 1 | 2014 | 148 | 0.100 |
Why?
| | Somatosensory Disorders | 1 | 2012 | 1 | 0.100 |
Why?
| | Animals, Laboratory | 1 | 2012 | 13 | 0.100 |
Why?
| | DNA Primers | 2 | 2012 | 508 | 0.100 |
Why?
| | Macaca mulatta | 1 | 2013 | 131 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1310 | 0.100 |
Why?
| | Immunotherapy | 2 | 2013 | 473 | 0.100 |
Why?
| | Macaca | 1 | 2012 | 50 | 0.100 |
Why?
| | Glycosylation | 4 | 2013 | 130 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 102 | 0.100 |
Why?
| | Neoplasm Transplantation | 2 | 2013 | 227 | 0.100 |
Why?
| | Edema | 1 | 2012 | 119 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2018 | 9049 | 0.090 |
Why?
| | Platelet Count | 2 | 2013 | 79 | 0.090 |
Why?
| | Protein Binding | 5 | 2014 | 1888 | 0.090 |
Why?
| | Rats | 2 | 2017 | 4913 | 0.090 |
Why?
| | Organ Transplantation | 1 | 2013 | 159 | 0.090 |
Why?
| | CD40 Ligand | 1 | 2010 | 37 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 695 | 0.090 |
Why?
| | Antigens, CD | 2 | 2003 | 440 | 0.090 |
Why?
| | Lymphocytes | 2 | 2021 | 327 | 0.090 |
Why?
| | Prednisolone | 1 | 2010 | 75 | 0.090 |
Why?
| | Injections, Subcutaneous | 1 | 2010 | 134 | 0.090 |
Why?
| | Blood Proteins | 2 | 2022 | 222 | 0.090 |
Why?
| | Sus scrofa | 2 | 2012 | 45 | 0.080 |
Why?
| | Leukocytosis | 1 | 2009 | 34 | 0.080 |
Why?
| | Immunization | 1 | 2012 | 397 | 0.080 |
Why?
| | Immunophenotyping | 2 | 2007 | 274 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 381 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2012 | 292 | 0.080 |
Why?
| | Pluripotent Stem Cells | 2 | 2014 | 64 | 0.080 |
Why?
| | Bone Marrow Cells | 3 | 2006 | 266 | 0.080 |
Why?
| | Antigens | 1 | 2010 | 317 | 0.080 |
Why?
| | Anemia | 1 | 2009 | 143 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 714 | 0.080 |
Why?
| | Prognosis | 3 | 2022 | 3315 | 0.080 |
Why?
| | Macaca fascicularis | 2 | 2018 | 50 | 0.070 |
Why?
| | Cell Line | 3 | 2021 | 2629 | 0.070 |
Why?
| | Varicellovirus | 1 | 2007 | 26 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 149 | 0.070 |
Why?
| | Models, Molecular | 1 | 2011 | 1368 | 0.070 |
Why?
| | Granulocyte Precursor Cells | 1 | 2006 | 7 | 0.070 |
Why?
| | Haploidy | 1 | 2006 | 21 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1875 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2010 | 526 | 0.070 |
Why?
| | Species Specificity | 3 | 2015 | 541 | 0.060 |
Why?
| | Female | 8 | 2022 | 59324 | 0.060 |
Why?
| | Pregnancy | 4 | 2015 | 5499 | 0.060 |
Why?
| | Tissue Donors | 2 | 2005 | 314 | 0.060 |
Why?
| | Cross Reactions | 2 | 2016 | 118 | 0.060 |
Why?
| | Allografts | 2 | 2015 | 121 | 0.060 |
Why?
| | Blood Group Incompatibility | 1 | 2004 | 12 | 0.060 |
Why?
| | Models, Animal | 3 | 2015 | 340 | 0.060 |
Why?
| | Erythroid Precursor Cells | 1 | 2003 | 4 | 0.060 |
Why?
| | Fetal Diseases | 1 | 2005 | 146 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 3397 | 0.060 |
Why?
| | Blotting, Southern | 1 | 2003 | 68 | 0.060 |
Why?
| | Uterus | 1 | 2005 | 191 | 0.060 |
Why?
| | Stem Cell Factor | 1 | 2003 | 14 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2003 | 15 | 0.050 |
Why?
| | Multipotent Stem Cells | 1 | 2003 | 17 | 0.050 |
Why?
| | Neoplasms | 1 | 2017 | 2086 | 0.050 |
Why?
| | Granulocytes | 1 | 2003 | 75 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 2023 | 70 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2005 | 163 | 0.050 |
Why?
| | Hindlimb | 1 | 2004 | 130 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2015 | 2173 | 0.050 |
Why?
| | Oximetry | 1 | 2023 | 79 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2002 | 13 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3521 | 0.050 |
Why?
| | Binding, Competitive | 2 | 2014 | 192 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1836 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2007 | 3861 | 0.050 |
Why?
| | Gestational Age | 1 | 2005 | 761 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.050 |
Why?
| | Gene Knockout Techniques | 2 | 2013 | 98 | 0.050 |
Why?
| | Gammaherpesvirinae | 1 | 2002 | 38 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 68 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 94 | 0.050 |
Why?
| | Solubility | 2 | 2012 | 223 | 0.050 |
Why?
| | Fetus | 1 | 2005 | 698 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 124 | 0.050 |
Why?
| | Male | 7 | 2022 | 55396 | 0.050 |
Why?
| | Protein Multimerization | 2 | 2014 | 157 | 0.050 |
Why?
| | Genome, Viral | 1 | 2002 | 118 | 0.050 |
Why?
| | Cell Separation | 1 | 2002 | 290 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2014 | 489 | 0.040 |
Why?
| | Rabbits | 2 | 2013 | 733 | 0.040 |
Why?
| | Monocytes | 1 | 2003 | 503 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 186 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 227 | 0.040 |
Why?
| | Cytokines | 2 | 2022 | 1824 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2022 | 383 | 0.040 |
Why?
| | Viral Proteins | 1 | 2022 | 281 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 2 | 2013 | 399 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 74 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 429 | 0.040 |
Why?
| | DNA | 2 | 2017 | 1350 | 0.040 |
Why?
| | Risk | 1 | 2022 | 810 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2017 | 2562 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 851 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 475 | 0.040 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2017 | 2 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1791 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 258 | 0.030 |
Why?
| | Herpesvirus 1, Suid | 1 | 2015 | 1 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 845 | 0.030 |
Why?
| | Tumor Virus Infections | 1 | 2015 | 43 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2015 | 58 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2537 | 0.030 |
Why?
| | National Eye Institute (U.S.) | 1 | 2014 | 6 | 0.030 |
Why?
| | Cell Engineering | 1 | 2014 | 7 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1014 | 0.030 |
Why?
| | Regenerative Medicine | 1 | 2014 | 41 | 0.030 |
Why?
| | Random Allocation | 1 | 2014 | 328 | 0.030 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 106 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2013 | 14 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 50 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2013 | 215 | 0.030 |
Why?
| | Antigens, CD34 | 1 | 2013 | 88 | 0.030 |
Why?
| | Hematocrit | 1 | 2013 | 86 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2014 | 193 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 129 | 0.030 |
Why?
| | Drug Design | 1 | 2013 | 147 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2012 | 51 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 345 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 376 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2005 | 415 | 0.020 |
Why?
| | Risk Factors | 1 | 2004 | 8614 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1143 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6195 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 304 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1690 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 453 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 926 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2007 | 1310 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 868 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2007 | 117 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
| | Middle Aged | 2 | 2022 | 26605 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2007 | 218 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 12521 | 0.020 |
Why?
| | Splenectomy | 1 | 2005 | 51 | 0.020 |
Why?
| | Risk Assessment | 1 | 2014 | 2958 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4680 | 0.020 |
Why?
| | Adult | 2 | 2022 | 30375 | 0.020 |
Why?
| | Aged | 1 | 2022 | 18969 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1003 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 248 | 0.010 |
Why?
| | Creatinine | 1 | 2005 | 424 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 565 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 265 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1471 | 0.010 |
Why?
| | Hybridomas | 1 | 2002 | 230 | 0.010 |
Why?
| | Genes, Viral | 1 | 2002 | 89 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2002 | 323 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 353 | 0.010 |
Why?
| | Benzimidazoles | 1 | 2002 | 137 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 522 | 0.010 |
Why?
| | Bone and Bones | 1 | 2004 | 277 | 0.010 |
Why?
| | Mammals | 1 | 2002 | 241 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 298 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 863 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2550 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 722 | 0.010 |
Why?
| | Kidney | 1 | 2005 | 1182 | 0.010 |
Why?
| | Phylogeny | 1 | 2002 | 787 | 0.010 |
Why?
| | United States | 1 | 2014 | 12137 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2314 | 0.010 |
Why?
|
|
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|